YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) in South Korea for a Phase 1...
Hence then, the article about gc biopharma submits ind application for phase 1 clinical trial of covid 19 mrna vaccine in korea was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea )
Also on site :
- Nvidia’s Jensen Huang was the Jenga piece to a towering multi-trillion AI industry. Will his exit set off a chain reaction?
- ‘The Amazing Race’s Michelle and Matt Patterson Reveal the Surprising Team They Tried to Form an Alliance With (Exclusive)
- Documentaries at the Oscars: A History of Breaking Out of Their Category — and What It Means for ‘You Can See Everything’